Recurrent Malignant Testicular Germ Cell Tumor Completed Phase 1 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0028803 (Recurrent Malignant Testicular Germ Cell Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00028496Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerTreatment